146514-35-4

Basic information

• Product Name: Carbamic acid, (tetrahydro-2-oxo-3-furanyl)-, 1,1-dimethylethyl ester
• CAS NO: 146514-35-4
• Molecular Formula: C9H15NO4
• Molecular Weight: 201.222
• Mol File: 146514-35-4.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Carbamic acid, (tetrahydro-2-oxo-3-furanyl)-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, (tetrahydro-2-oxo-3-furanyl)-, 1,1-dimethylethyl ester(146514-35-4)
• EPA Substance Registry System: Carbamic acid, (tetrahydro-2-oxo-3-furanyl)-, 1,1-dimethylethyl ester(146514-35-4)

Safety Data

• Hazardous Substances Data: 146514-35-4(Hazardous Substances Data)

Usage

General Description

Carbamic acid, (tetrahydro-2-oxo-3-furanyl)-, 1,1-dimethylethyl ester, also known as furanomycin, is an organic compound that is commonly used as an intermediate in organic synthesis. It is a colorless liquid with a fruity odor and is soluble in water and most organic solvents. This chemical is commonly used in the production of pharmaceuticals, agrochemicals, and other fine chemicals. It is also used as a solvent and reagent in various chemical reactions. However, it is important to handle this chemical with caution as it can be harmful if ingested, inhaled, or if it comes into contact with the skin or eyes.

Upstream product

• 38308-92-8 2-(tert-butoxycarbonylamino)-4-hydroxy-butanoic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1192-20-7 2-aminobutyrolactone 
• 254882-48-9 methyl O-benzyl-N-(tert-butoxycarbonyl)-L-homoserinate 
• 146514-21-8 N-Boc-2-methyltetrahydro-1,3-oxazine 
• 6305-38-0 α-amino-γ-butyrolactone hydrobromide 
• 124-38-9 carbon dioxide 

Downstream Products

• 128427-10-1 (S)-2-(tert-butoxycarbonylamino)-1,4-butanediol 
• 397246-14-9 (1-(hydroxymethyl)-3-hydroxypropyl)carbamic acid tert-butyl ester 
• 1205603-10-6 {1-[5-(4-Fluoro-phenoxy)-4-(4-fluoro-phenyl)-thiazol-2-ylcarbamoyl]-3-hydroxy-propyl}-carbamic acid tert-butyl ester 
• 132872-28-7 N-benzyl-N-<1-(2'-benzyloxyethyl)-3-methylbut-2-enyl>-N-(tert-butoxycarbonyl)amine 
• 79349-56-7 N-tert-butyloxycarbonyl-DL-homoserine benzhydryl ester 
• 38308-92-8 2-(tert-butoxycarbonylamino)-4-hydroxy-butanoic acid 
• 132872-26-5 2-(tert-butoxycarbonylamino)-γ-butyrolactol 
• 156627-42-8 2-(tert-butoxycarbonylamino)butane-1,4-diol 

Relevant articles and documents

Structure-activity study of new inhibitors of human betaine-homocysteine S-methyltransferase

Betaine-homocysteine S-methyltransferase (BHMT) catalyzes the transfer of a methyl group from betaine to L-homocysteine, yielding dimethylglycine and L-methionine. In this study, we prepared a new series of BHMT inhibitors. The inhibitors were designed to mimic the hypothetical transition state of BHMT substrates and consisted of analogues with NH, N(CH3), or N(CH 3)2 groups separated from the homocysteine sulfur atom by a methylene, ethylene, or a propylene spacer. Only the inhibitor with the N(CH3) moiety and ethylene spacer gave moderate inhibition. This result led us to prepare two inhibitors lacking a nitrogen atom in the S-linked alkyl chain: (RS,RS)-5-(3-amino-3-carboxypropylthio)-3-methylpentanoic acid and (RS)-5-(3-amino-3-carboxypropylthio)-3,3-dimethylpentanoic acid. Both of these compounds were highly potent inhibitors of BHMT. The finding that BHMT does not tolerate a true betaine mimic within these inhibitors, especially the nitrogen atom, is surprising and evokes questions about putative conformational changes of BHMT upon the binding of the substrates/products and inhibitors.

Cyclic hydroxamates, especially multiply substituted [1,2]oxazinan-3-ones

Routes to putative N-acyl-D-ala-D-ala surrogates, beginning with the conversion of 4-, 5-, and 6-membered lactones into 5-, 6-, and 7-membered cyclic hydroxamates, are reported. The key step of the synthesis is trimethylaluminium-promoted cyclization of an ω-aminooxyester. The 7-membered cyclic hydroxamate crystallizes in a chair conformation. Extension of the reaction sequence to homoserine or homoserine lactone leads to cyclocanaline and N-acylated cyclocanalines. The 4-phenylacetamido derivative of cyclocanaline crystallizes in a boat conformation. The attachment of a 2-carboxypropyl substituent to the ring nitrogen of a 4-acylaminocyclocanaline has been effected, prior to cyclization, by coupling of the acyclic aminooxyester precursor to the triflate of benzyl lactate or, after cyclization, by coupling to tert-butyl α-bromopropionate in the presence of potassium fluoride - alumina, followed by removal of the protecting group in each case. A six-membered homolog of the antibiotic lactivicin has been synthesized by the reaction of 4-phenylacetamidocyclocanaline with benzyl 2-oxoglutarate in the presence of carbodiimide, followed by hydrogenolysis. Starting with methyl 2,4-dibromo-2,4-dideoxy-L-erythronate, which is available in two steps from L-ascorbic acid, these reaction sequences have been applied to the stereospecific synthesis of a D-alanine derivative whose nitrogen atom is enclosed within a 3,4-disubstituted [1,2]oxazinan-3-one.

Platelet aggregation inhibitors

This invention relates to compounds having the following formula STR1 or a pharmaceutically acceptable salt thereof which are useful in the inhibition of platelet aggregation, to pharmaceutical compositions of such phenylamidines derivatives, and to a method of inhibiting platelet aggregation in mammals by administering such compounds and compositions.